Skip to main content
NCD 240.1 · version 3

NCD 240.1: Lung Volume Reduction Surgery (Reduction Pneumoplasty)

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: Medicare Coverage Database release of September 24, 2026 (effective September 20, 2026). Next CMS release: weekly (every Thursday) for the MCD; quarterly for lab NCD code lists.

Key facts for NCD 240.1

Benefit category
Inpatient Hospital Services, Outpatient Hospital Services Incident to a Physician's Service, Physicians' Services
Effective date
11/17/2005
Implemented 03/02/2006
Transmittal
Transmittal 44
Versions published
3
Manual chapter
240
NCD Manual (Pub. 100-03)

TL;DR

NCD 240.1 sets Medicare's national policy for lung volume reduction surgery (reduction pneumoplasty) under the benefit category "Inpatient Hospital Services, Outpatient Hospital Services Incident to a Physician's Service, Physicians' Services", effective 11/17/2005 and implemented 03/02/2006. Effective for services performed on or after January 1, 2004 Medicare will only consider LVRS reasonable and necessary when all of the following requirements are met (note varying dates for facility criteria in section 3. below): It has been revised 2 times since publication and binds every Medicare Administrative Contractor nationally.

Item or service described

A. General

Lung volume reduction surgery (LVRS) or reduction pneumoplasty, also referred to as lung shaving or lung contouring, is performed on patients with severe emphysema in order to allow the remaining compressed lung to expand, and thus, improve respiratory function. Medicare-covered LVRS approaches are limited to bilateral excision of a damaged lung with stapling performed via median sternotomy or video-assisted thoracoscopic surgery.

Indications and limitations of coverage

B. Nationally Covered Indications

Effective for services performed on or after January 1, 2004 Medicare will only consider LVRS reasonable and necessary when all of the following requirements are met (note varying dates for facility criteria in section 3. below):

1. The patient satisfies all the criteria outlined below:

Assessment

Criteria

History and physical examination

Consistent with emphysema

BMI, ≤31.1 kg/m 2 (men) or ≤ 32.3 kg/m 2 (women)

Stable with ≤ 20 mg prednisone (or equivalent) qd

Radiographic

High Resolution Computer Tomography (HRCT) scan evidence of bilateral emphysema

Pulmonary function (pre-rehabilitation)

Forced expiratory volume in one second (FEV 1 ) ≤ 45% predicted ≥ 15% predicted if age ≥ 70 years)

Total lung capacity (TLC) ≥ 100% predicted post-bronchodilator

Residual volume (RV) ≥ 150% predicted post-bronchodilator

Arterial blood gas level (pre-rehabilitation)

PCO 2 , ≤ 60 mm Hg (PCO 2 , ≤ 55 mm Hg if 1-mile above sea level)

PO 2 , ≥ 45 mm Hg on room air (PO 2 , ≥ 30 mm Hg if 1-mile above sea level)

Cardiac assessment

Approval for surgery by cardiologist if any of the following are present: Unstable angina; left-ventricular ejection fraction (LVEF) cannot be estimated from the echocardiogram; LVEF 5 premature ventricular contractions per minute; cardiac rhythm other than sinus; premature ventricular contractions on EKG at rest)

Surgical assessment

Approval for surgery by pulmonary physician, thoracic surgeon, and anesthesiologist post-rehabilitation

Exercise

Post-rehabilitation 6-min walk of ≥ 140 m; able to complete 3 min unloaded pedaling in exercise tolerance test (pre- and post-rehabilitation)

Consent

Signed consents for screening and rehabilitation

Smoking

Plasma cotinine level ≤13.7 ng/mL (or arterial carboxyhemoglobin ≤ 2.5% if using nicotine products)

Nonsmoking for 4 months prior to initial interview and throughout evaluation for surgery

Preoperative diagnostic and therapeutic program adherence

Must complete assessment for and program of preoperative services in preparation for surgery

2. In addition, the patient must have:

• Severe upper lobe predominant emphysema (as defined by radiologist assessment of upper lobe predominance on CT scan), or

• Severe non-upper lobe emphysema with low exercise capacity.

Patients with low exercise capacity are those whose maximal exercise capacity is at or below 25 watts for women and 40 watts (w) for men after completion of the preoperative therapeutic program in preparation for LVRS. Exercise capacity is measured by incremental, maximal, symptom-limited exercise with a cycle ergometer utilizing 5 or 10 watt/minute ramp on 30% oxygen after 3 minutes of unloaded pedaling.

3. Effective for services performed on or after November 17, 2005, CMS determines that LVRS is reasonable and necessary when performed at facilities that are:

(1) certified by the Joint Commission on Accreditation of Healthcare Organizations (Joint Commission) under the LVRS Disease Specific Care Certification Program (program standards and requirements as printed in the Joint Commission’s October 25, 2004, Disease Specific Care Certification Program packet); or (2) approved as Medicare lung or heart-lung transplantation hospitals.

In addition, LVRS performed between January 1, 2004, and May 17, 2007, is reasonable and necessary when performed at facilities that: (1) were approved by the National Heart Lung and Blood Institute to participate in the National Emphysema Treatment Trial (NETT); or (2) are approved as Medicare lung or heart-lung transplantation hospitals.

A list of approved facilities and their approval dates will be listed and maintained on the CMS Web site at http://www.cms.gov/Medicare/Medicare-General-Information/MedicareApprovedFacilitie/04_lvrs.asp#TopOfPage .

The surgery must be preceded and followed by a program of diagnostic and therapeutic services consistent with those provided in the NETT and designed to maximize the patient's potential to successfully undergo and recover from surgery. The program must include a 6- to 10-week series of at least 16, and no more than 20, preoperative sessions, each lasting a minimum of 2 hours. It must also include at least 6, and no more than 10, postoperative sessions, each lasting a minimum of 2 hours, within 8 to 9 weeks of the LVRS. This program must be consistent with the care plan developed by the treating physician following performance of a comprehensive evaluation of the patient's medical, psychosocial and nutritional needs, be consistent with the preoperative and postoperative services provided in the NETT, and arranged, monitored, and performed under the coordination of the facility where the surgery takes place.

C. Nationally Non-covered Indications

1. LVRS is not covered in any of the following clinical circumstances:

• Patient characteristics carry a high risk for perioperative morbidity and/or mortality;

• The disease is unsuitable for LVRS;

• Medical conditions or other circumstances make it likely that the patient will be unable to complete the preoperative and postoperative pulmonary diagnostic and therapeutic program required for surgery;

• The patient presents with FEV1 ≤ 20% of predicted value, and either homogeneous distribution of emphysema on CT scan, or carbon monoxide diffusing capacity of ≤ 20% of predicted value (high-risk group identified October 2001 by the NETT); or

• The patient satisfies the criteria outlined above in section B(1), and has severe, non-upper lobe emphysema with high exercise capacity. High exercise capacity is defined as a maximal workload at the completion of the preoperative diagnostic and therapeutic program that is above 25 w for women and 40 w for men (under the measurement conditions for cycle ergometry specified above).

2. All other indications for LVRS not otherwise specified remain noncovered.

(This NCD last reviewed November 2005.)

Text reproduced from the CMS Medicare Coverage Database record for NCD 240.1 version 3. View the original on cms.gov.

Revision history

12/2005 - Modified requirements for facilities eligible to perform lung volume reduction surgery. Effective Date: 11/17/2005. Implementation Date: 03/02/2006. ( TN 44 ) CR4149

11/2003 - Expanded coverage to include patients who are: (1) Non high-risk and present with severe, upper-lobe emphysema; or, (2) Non high-risk and present with severe, non upper-lobe emphysema with low exercise capacity. Effective date 1/01/2004. Implementation date 1/5/2004. M+C Implementation date 4/5/2004. ( TN 3 ) (CR 2688)

07/1997 - Provided coverage policy. Effective date 08/11/1997. (TN 102)

12/1995 - Provided noncoverage policy. Effective date NA. (TN 83)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

How QuickIntell applies NCD 240.1

QuickAuth checks the ordered service and diagnosis against NCD and LCD criteria before the encounter, QuickCode validates the diagnosis pairing on the claim, and QuickRCM routes CARC 50 denials with the policy text and the covered-code list attached so the appeal starts with evidence.

Frequently asked questions — NCD 240.1

What does NCD 240.1 cover?

Effective for services performed on or after January 1, 2004 Medicare will only consider LVRS reasonable and necessary when all of the following requirements are met (note varying dates for facility criteria in section 3. below): The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 240.1 take effect?

The current version (3) is effective 11/17/2005, implemented 03/02/2006, published in transmittal 44. CMS lists 3 versions of this NCD.

Does a Local Coverage Determination override NCD 240.1?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-02. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.